Jazz Pharmaceuticals
NasdaqGS:JAZZ Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 28 Fair Values set on narratives written by author
WA
Consensus Narrative from 19 Analysts
Upcoming Approvals For Zepzelca, Zanidatamab, And Xywav Will Strengthen Global Market Presence
Key Takeaways Successful trial outcomes and strategic expansions for Zepzelca, Zanidatamab, and Xywav drive expectations of significant revenue growth and market strength. Strategic investments and commercial execution enhance global presence, supporting sustained earnings growth and strong cash flow for Jazz Pharmaceuticals.
View narrativeUS$181.05
FV
26.0% undervalued intrinsic discount5.78%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
19 days ago author updated this narrative